Introduction {#Sec1}
============

Intensity-modulated radiotherapy (IMRT) is the main treatment that facilitates the delivery of high radiation doses to the target and reduces the delivered dose to organs. IMRT shows excellent local control with few toxicities \[[@CR1]\]. However, during IMRT, a significant shrinkage of the tumours and weight loss may occur in patients with nasopharyngeal carcinoma (NPC), and these changes can result in the delivery of decreased radiation doses to the tumour and increased doses to normal tissues \[[@CR2]\]. Adaptive radiotherapy (ART) instantly corrects the target and dose based on repeat computed tomography (CT) imaging from each patient and re-planning during the course of IMRT to identify dosimetric changes and ensure the delivery of adequate doses to target volumes and safe doses to normal tissues; thus, ART can significantly alleviate late effects (injury to the mucosa and xerostomia) in patients \[[@CR3], [@CR4]\].

Studies show that 30--60% of patients with head and neck cancer (HNC) suffer from malnutrition caused by complex factors, including swallowing pain, anorexia and radiotherapy-induced symptoms, all of which impair the patient's ability to eat, and many patients lose additional weight during and after treatment \[[@CR5], [@CR6]\]. These factors greatly aggravate malnutrition of patients during radiotherapy; additionally, poor nutritional status is significantly associated with poor prognosis in patients with head and neck squamous cell carcinoma \[[@CR7]--[@CR9]\]. ART can limit oral side effects and xerostomia resulting from radiation-induced damage mainly to the parotid glands (PGs) \[[@CR4], [@CR10]\], thereby enhancing the nutritional intake of patients and improving nutrition during and after radiotherapy.

With the rising incidence of HNC, the TNM staging system remains inadequate, and it is becoming increasingly important to find reliable prognostic parameters \[[@CR11], [@CR12]\]. Many studies have suggested that haematological parameters such as platelet counts and the neutrophil-to-lymphocyte ratio (NLR) can be used as indicators to predict the prognosis of cancer patients \[[@CR8], [@CR13]--[@CR19]\]. Several pretherapeutic laboratory values, such as red cell count, have prognostic relevance for overall survival (OS) in patients with HNC \[[@CR20]\].

Lou Y et al. found that compared with IMRT alone, IMRT re-planning facilitates improved local--regional recurrence-free survival (LRFS) in patients with stage T3/T4 NPC \[[@CR21]\]. Several studies had previously proposed that nutritional status and haematological parameters during radiotherapy are associated with prognosis in patients with head and neck squamous cell carcinoma \[[@CR7], [@CR8], [@CR13], [@CR14]\]. In recent years, studies have suggested that nutritional status and haematological parameters are related to prognosis, but the correlation between ART and haematological indicators, such as the NLR, has never been reported. This study intends to explore the influence of ART on the change in haematological indicators and provide a theoretical basis for the use of ART in patients with NPC.

Material and methods {#Sec2}
====================

Patients {#Sec3}
--------

We included 122 newly diagnosed patients with histologically confirmed nonmetastatic NPC, who received radical radiotherapy with or without concurrent chemotherapy (CCT) in our hospital between January 2014 and December 2015 (Fig. [1](#Fig1){ref-type="fig"}). All patients were staged according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system \[[@CR22]\]. This study was approved by the ethics committee of our hospital. Informed consent was obtained. Fig. 1Overall study flow chart. Abbreviations: IMRT,Intensity-modulated radiotherapy; ART, adaptive radiotherapy

IMRT {#Sec4}
----

All patients received IMRT with 6-megavoltage (MV) photons. The gross tumour target of the nasopharynx (GTVnx) and involved lymph nodes (GTVln) were outlined based on CT and magnetic resonance imaging (MRI) scans. The clinical target volume 1 (CTV1) included the GTVnx with a 5--10 mm margin and high risk structures. The clinical target volume 2 (CTV2) included regions of the nasopharyngeal cavity, maxillary sinus, pterygopalatine fossa, posterior ethmoid sinus, parapharyngeal space, skull base, anterior third of clivus, inferior sphenoid sinus, and cavernous sinus. The clinical lymph node volume (CTVln) included the upper neck lymphatic drainage regions. Organs at risk (OAR) were also outlined. The contoured critical structures included the brain stem, chiasm, optic nerves, spinal cord, eyes, lens, PGs, oral cavity, larynx, mandible, and temporomandibular joints. The prescribed doses were defined as follows: 66--70 Gy for GTVnx and GTVln; 60 Gy for CTV1; and 50 Gy for CTV2. Each dose was divided into 28--33 fractions. The dose limits for normal organs were set according to the Radiation Therapy Oncology Group (RTOG) protocol 0225 \[[@CR23]\].

Art {#Sec5}
---

All patients underwent weekly CT scanning. During each repeat CT scan, the patient maintained the same position, and the new CT scan was used to generate a new IMRT plan for the corresponding fractions of treatment. During the treatment, if re-planning was necessary, the target and OAR were re-contoured as required on the repeat CT scan and a new plan generated (Fig. [2](#Fig2){ref-type="fig"}). The aim of the new plan was to achieve comparable target volume coverage and OAR doses to the original plan. Fig. 2Survival analysis of the IMRT group and the ART+IMRT group. Abbreviations: OS, overall survival; LRFS, local--regional recurrence-free survival; DMFS, distant metastasis-free survival;PFS, progression-free survival

CCT {#Sec6}
---

CCT, which included cisplatin (75 mg/m2, days 1--3), was given to all patients.

Haematological parameters {#Sec7}
-------------------------

Five parameters, namely, changes during radiotherapy in the NLR (ΔNLR), the circulating lymphocyte count (ΔCLC), the circulating platelet count (ΔCPC), the circulating neutrophil granulocyte count (ΔCNC), and the haemoglobin count (ΔHB), were analysed. The ΔNLR during radiotherapy is the result of subtraction of the count before radiotherapy (NLR1) from the count after radiotherapy (NLR2) divided by the count before radiotherapy (NLR1): ΔNLR = NLR2-NLR1/NLR1. The ΔCLC during radiotherapy is the result of subtraction of the CLC before radiotherapy (CLC1) from the CLC after radiotherapy (CLC2) divided by the CLC before radiotherapy (CLC1): ΔCLC = (CLC2-CLC1)/CLC1. The ΔCNC during radiotherapy is the result of subtraction of the CNC before radiotherapy (CNC1) from the CNC after radiotherapy (CNC2) divided by the CNC before radiotherapy (CNC1): ΔCNC = (CNC2-CNC1)/CNC1. The ΔCPC during radiotherapy is the result of subtraction of the CPC before radiotherapy (CPC1) from the CPC after radiotherapy (CPC2) divided by the CPC before radiotherapy (CPC1): ΔCPC = (CPC2-CPC1)/CPC1. The ΔHB during radiotherapy is the result of the subtraction of HB before radiotherapy (HB1) from HB after radiotherapy (HB2) divided by HB before radiotherapy (HB1): ΔHB = (HB2-HB1)/HB1.

Follow-up {#Sec8}
---------

All patients were evaluated weekly during radiotherapy and examined in follow-up appointments that were scheduled up to 1 month after the completion of radiotherapy and then every 3 months in years 1--2, every 6 months in years 3--5, and annually thereafter. Each follow-up included a flexible fibreoptic endoscopy, abdominal ultrasound, chest X-ray and basic serum chemistry. Either CT or MRI of the head and neck was also performed after the completion of IMRT and every 6 months thereafter.

Statistics {#Sec9}
----------

Propensity score matching was used to divide the patients into two groups (IMRT and ART+IMRT). A one-to-one matching without replacement was performed using a 0.5 caliper width. The χ2 test and paired t test were used to test the baseline balance between the two groups. The relationship between the change in haematological parameters and treatment-related factors was analysed by Pearson's correlation. Variables with *P* \< 0.05 were included in a multivariate analysis, performed by regression analysis. Subgroup analyses were performed using paired t tests. The rates of LRFS, distant metastasis-free survival (DMFS), progression-free survival (PFS) and OS were estimated with the Kaplan--Meier method and compared with the log-rank test. All data were analysed using SPSS 22.0 software package (IBM Corporation, Armonk, NY, USA).

Results {#Sec10}
=======

Patients and characteristics {#Sec11}
----------------------------

After matching, 55 and 67 patients were treated with ART+IMRT and IMRT, respectively. Among them, 50 patients treated with ART+IMRT and 50 patients with IMRT were included in the analysis. All subsequent analyses were based on the propensity-matched cohort. The characteristics of patients after propensity score matching are shown in Table [1](#Tab1){ref-type="table"}. Table 1Patient characteristics and treatment details after propensity score matchingCharacteristicsART+IMRT\
(*n* = 50)IMRT\
(n = 50)PAge (years)54 (16\~72)55 (22\~73)0.865Gender0.500 Male33 (66%)34 (68%) Female17 (34%)16 (32%)History of smoking0.500 Yes22 (44%)23 (46%) No28 (56%)27 (54%)History of drinking0.795 Yes8 (16%)10 (20%) No42 (84%)40 (80%)Family history0.795 Yes10 (20%)8 (16%) No40 (80%)42 (84%)T stage1 T11 (2%)1 (2%) T229 (58%)29 (58%) T314 (28%)14 (28%) T46 (12%)6 (12%)N stage1 N07 (14%)7 (14%) N111 (22%)11 (22%) N227 (54%)27 (54%) N35 (10%)5 (10%)Clinical stage1 II3 (6%)3 (6%) III40 (80%)40 (80%) IV7 (14%)7 (14%) CCT50 (100%)50 (100%)1*Abbreviations*: *IMRT* Intensity-modulated radiotherapy, *ART* adaptive radiotherapy, *CCT* concurrent chemotherapy

Changes in haematological parameters in different radiotherapy modes {#Sec12}
--------------------------------------------------------------------

There were no significant differences in the pre-treatment NLR, CLC, CPC, or CNC between the two groups, while the differences in the ΔNLR (*P* = 0.002), ΔCLC (*P* \< 0.001), and ΔCPC (*P* = 0.036) were statistically significant. Differences in acute radiation injury classification of the PGs (P \< 0.001), skin (P \< 0.001) and oral structures (P \< 0.001) were also significant in both groups and are shown in Table [2](#Tab2){ref-type="table"}. We also compared Δweight (kg) and Δweight (%) for the two groups during radiotherapy and observed a significant difference (*P* = 0.025 and *P* = 0.030, respectively). Table 2Comparison of radiotherapy-related variables between the two groupsCharacteristicsART+IMRT(n = 50)IMRT(n = 50)PPre-NLR2.00 ± 1.782.81 ± 2.540.076Pre-CLC(10^9^/L)1.54 ± 0.601.66 ± 0.760.381Pre-CNC(10^9^/L)4.12 ± 1.654.16 ± 1.870.907Pre-CPC(10^9^/L)222.9 ± 63.02239.8 ± 59.930.155Pre-HB(g/L)143.26 ± 15.46138.92 ± 44.150.534ΔNLR(%)−1.80 ± 114.0270.34 ± 49.40\< 0.001^\*^ΔCLC(%)− 126.33 ± 119.97−341.36 ± 320.99\< 0.001^\*^ΔCNC(%)−14.43 ± 65.43−30.57 ± 89.830.288ΔCPC(%)−4.52 ± 23.15−16.62 ± 32.070.036^\*^ΔHCG(%)45.68 ± 11.19−45.7 ± 26.880.303Δweight (Kg)−3.76 ± 3.13−5.04 ± 2.090.025^\*^ΔWeight(%)−7.99 ± 3.60−5.98 ± 4.870.030^\*^Acute radiation injury classification Parotid glands\< 0.001^\*^  000  1130  23750  300  400 Skin\< 0.001^\*^  020  13818  2926  316  400 Oral\< 0.001^\*^  080  1014  22812  31424  400*Abbreviations*: *NLR* neutrophil-to-lymphocyte ratio, *CLC* circulating lymphocyte count, *CPC* circulating platelet count, *CNC* circulating neutrophil granulocyte count, *HB* the haemoglobin count^\*^*P* ≤ 0.05

Side effects were significantly different between the two groups; however a previous study had concluded that the mean dose (Dmean) to the PGs is related to xerostomia during the course of IMRT and that ART can decrease the Dmean to the PGs \[[@CR10]\]. Therefore, we compared Dmean and dose to 50% of the volume (D50) for the PGs and Dmean, D50, and the maximum dose for the skin. Additionally, we excluded 19 patients with missing weekly CT data in the IMRT group, and 19 matched patients in the ART+IMRT group were also excluded. Moreover, 1 patient without weekly CT data in the ART+IMRT group was excluded, and the matched patient in the IMRT group was also excluded. Hence, the new IMRT (IMRTnew) and the new ART+IMRT (ART+IMRTnew) groups were created, with 30 patients in each group. By comparison, differences in the Dmean, and D50 for the PGs and D50 for the skin were significant. For ipsilateral PGs, the difference in D50 and Dmean between the two groups was 1.28 Gy (*P* = 0.021) and 1.12 Gy (*P* = 0.038), respectively. For contralateral PGs, the difference in D50 and Dmean between the two groups was 1.28 Gy (P = 0.021) and 0.92 Gy (*P* = 0.034), respectively. For the skin, the difference in D50 between the two groups was 11.85 Gy (*P* \< 0.001) (Table [3](#Tab3){ref-type="table"}). Table 3Dosimetric changes in the OAROARsART+IMRT new\
No.GyIMRT new\
No.GyPPG-ips D5026.11 ± 6.1227.39 ± 7.190.021^\*^ Dmean28.68 ± 5.9929.80 ± 7.120.038^\*^PG-con D5024.69 ± 3.9225.95 ± 4.200.009^\*^ Dmean27.10 ± 4.0128.02 ± 4.380.034^\*^Skin D503.03 ± 3.1814.88 ± 6.65\< 0.001^\*^ Dmean21.22 ± 22.2718.52 ± 4.210.491 Dmax70.64 ± 5.5271.29 ± 5.410.076*Abbreviations*: *OAR* organs at risk, *PGs* parotid glands, *Dmean* mean dose, *D50* dose to 50% of the volume, *IMRT new* the new IMRT, *ART+IMRT* new,the new ART+IMRT^\*^*P* ≤ 0.05

Changes in haematological parameters and related factors {#Sec13}
--------------------------------------------------------

Relevant variables were included in the correlation analysis and regression analysis. The ΔNLR, ΔCLC, and ΔCPC were normally distributed. In univariate analyses, clinical stage (R = -0.719, *P* = 0.001), ART (R = -0.721, *P* \< 0.001) and acute radiation injury grade of the skin (R = 0.536, P = 0.001) were significantly associated with the ΔNLR. Additionally, ART was significantly associated with the ΔCLC (R = 2.150, P \< 0.001), and ART (R = 0.121, *P* = 0.035) was the only significantly correlated factor with the ΔCPC (Table [4](#Tab4){ref-type="table"}). Table 4Univariate analysis of the ΔNLR, ΔCLC, and ΔCPCCharacteristicsΔNLRΔCLCΔCPCRegression coefficientSDPPearson coefficientRegression coefficientSDPPearson coefficientRegression coefficientSDPPearson coefficientAge (years)0.0030.0090.7570.3100.0020.0250.9420.007−0.0030.0030.333−0.098Gender−0.2250.2030.270−0.111−0.7820.5640.169−0.139−0.0240.0610.702− 0.039History of smoking0.2020.1930.2970.105−0.0670.5430.902−0.013− 0.0670.0580.253−0.115History of drinking0.2210.2480.3750.0900.3750.6960.5910.0540.0500.0750.5030.068Family history−0.3540.2470.155−0.1430.1890.6970.7870.027−0.0310.0750.679−0.042T stage−0.2430.1290.064−0.1860.5930.3630.1050.1630.0170.0400.6620.044N stage−0.0150.1190.902−0.013−0.2080.3330.535−0.0630.0280.0360.4350.079Clinical stage−0.7190.2050.001^\*^−0.3341.0230.6000.0910.170−0.0150.0660.816−0.024ART−0.7210.177\< 0.001^\*^−0.3802.1500.490\< 0.001^\*^0.4060.1210.0570.035^\*^0.211Acute radiation injury classification Parotid glands0.4260.2820.1330.151−0.5940.7910.456−0.075− 0.0770.0860.370−0.091 Skin0.5360.136\< 0.001^\*^0.370−0.7850.4010.053−0.194−0.0460.0440.293−0.106 Oral0.1100.1040.2960.1060.3310.2910.2580.114−0.0010.0320.978−0.003*Abbreviations*: *ART* adaptive radiotherapy, *NLR* neutrophil-to-lymphocyte ratio, *CLC* circulating lymphocyte count, *CPC* circulating platelet count^\*^*P* ≤ 0.05

According to the results of univariable analyses, ART, acute radiation injury grade of the skin, and clinical stage were included in a multivariate analysis. Based on the results of the multivariate analysis, ART, acute radiation injury grade of the skin, and clinical stage were the influencing factors of the ΔNLR in patients (R = 0.531, *P* = 0.004; R = 0.328, *P* = 0.020; and R = -0.689, *P* \< 0.001, respectively). ART was further included in a multivariate regression analysis of ΔCLC. Because acute radiation injury grade of the skin had a *P* value of 0.053, close to 0.05, this factor was also included in the multivariate analysis. After calculation, the side effect to the skin was excluded, and ART was identified as the influencing factor of the ΔCLC (R = 2.108, *P* \< 0.001). ART was also the only factor that affected the ΔCPC (R = 0.121, *P* = 0.035) (Table [5](#Tab5){ref-type="table"}). Table 5Multivariate analysis of the ΔNLR, ΔCLC, and ΔCPCCharacteristicsΔNLRΔCLCΔCPCRegression coefficientSDStandard regression coefficientTPRegression coefficientSDStandard regression coefficientTPRegression coefficientSDStandard regression coefficientTPART− 0.5310.181− 0.280−2.9330.004^\*^2.1080.5490.3983.842\< 0.001^\*^0.1210.0570.2112.1410.035^\*^Acute injury of skin0.3280.1390.2262.3660.020^\*^−0.0730.419−0.018−0.1740.862----------Clinical stage−0.6890.185−0.320−3.727\< 0.001^\*^--------------------*Abbreviations*: *ART* adaptive radiotherapy, *NLR* neutrophil-to-lymphocyte ratio, *CLC* circulating lymphocyte count, *CPC* circulating platelet count^\*^*P* ≤ 0.05

Subgroup analysis {#Sec14}
-----------------

To identify patients who benefited the most from ART, we performed subgroup analyses according to the T stage (T1--2 and T3--4) and N stage (N0--2 and N3). The clinical stage was related to the ΔNLR during radiotherapy and was identified as an independent prognostic factor of the ΔNLR. However, there was not a wide distribution among clinical stages, and TNM staging is closely related to the clinical stage. Therefore, we performed subgroup analysis according to the TNM classification.

For patients with stage T1-4 N0--3 disease, the ΔNLR was higher in patients treated with IMRT than in patients treated with ART+IMRT (*P* = 0.018, *P* = 0.032, *P* = 0.029, and *P* = 0.004, respectively). For patients with T1--2N0--3 disease, the ΔCLC was higher in patients treated with ART+IMRT than in patients treated with IMRT (*P* \< 0.001, *P* = 0.003, and P = 0.003, respectively). These differences were significant (Table [6](#Tab6){ref-type="table"}). Table 6Comparison of the ΔNLR, ΔCLC, and ΔCPC in different subgroups according to TNM stagesCharacteristicsΔNLR(%)ΔCLC(%)ΔCPC(%)ART+IMRTIMRTPART+IMRTIMRTPART+IMRTIMRTPT stage 1--2(*n* = 30)15.61 ± 65.6959.03 ± 58.520.018^\*^−117.93 ± 88.14−406.47 ± 350.15\< 0.001^\*^−6.80 ± 20.87−19.07 ± 34.610.107 3--4(*n* = 20)−27.92 ± 157.7857.65 ± 34.570.032^\*^−138.93 ± 155.13−243.70 ± 240.360.095−1.1 ± 26.93−12.96 ± 29.240.199N stage 0--1(*n* = 18)2.17 ± 130.7876.54 ± 12.690.029^\*^−109.18 ± 107.03− 312.87 ± 219.520.003^\*^−6.21 ± 24.70−18.57 ± 25.470.171 2--3(*n* = 32)−4.03 ± 107.5966.85 ± 61.100.004^\*^− 135.98 ± 129.10− 357.39 ± 372.840.003^\*^−3.58 ± 22.97−15.53 ± 36.050.117*Abbreviations*: *ART* adaptive radiotherapy, *IMRT* Intensity-modulated radiotherapy, *NLR* neutrophil-to-lymphocyte ratio, *CLC* circulating lymphocyte count; CPC, circulating platelet count^\*^*P* ≤ 0.05

Survival {#Sec15}
--------

The median follow-up time in the IMRT group was 33 months (12.9--45.4 months), and that in the ART+IMRT group was 33.1 months (7.1--46.8 months). The differences in OS(Fig. [3](#Fig3){ref-type="fig"}a), PFS(Fig. [3](#Fig3){ref-type="fig"}b), LRFS(Fig. [3](#Fig3){ref-type="fig"}c), and DMFS(Fig. [3](#Fig3){ref-type="fig"}d) between these two groups were not statistically significant (*P* = 0.750, *P* = 0.659, *P* = 0.685 and *P* = 0.764, respectively) (Fig. [3](#Fig3){ref-type="fig"}). Local recurrence was found in 3 (6%) patients in the ART+IMRT group and in 9 (18%) patients in the IMRT group, with fewer local recurrences in the ART+IMRT group than in the IMRT group. Fig. 3ART flow chart. Weekly CT scans were performed during the treatment. Doses were calculated for each weekly fraction. Abbreviations: IMRT, Intensity-modulated radiotherapy; ART, adaptive radiotherapy; NPC, nasopharyngeal carcinoma; CT, computed tomography

Discussion {#Sec16}
==========

In this study, we found that ART reduces side effects during radiotherapy in patients with NPC. We compared the acute radiation injury responses of the PGs, skin and oral structures in the last week of radiotherapy, and the differences were obvious. The differences in the ART+IMRT group was significantly less pronounced than that in the IMRT group. The acute radiation response grade for the PGs was ≥2 after the treatment in 50 patients receiving IMRT, while this was true for 37 patients in the ART+IMRT group; likewise, the acute radiation response grade for the skin was ≥2 for 32 patients in the IMRT group and 10 patients in the ART+IMRT group. The reason was that ART decreased the radiation dose to normal tissues \[[@CR3], [@CR4]\]. The PGs are the most vulnerable organ during radiotherapy, regardless of volume or displacement, and the dose to the PGs results in the risk of xerostomia. Excess radiation dose to the PGs increases the risk of xerostomia, leading to a deterioration in the quality of life (QOL) \[[@CR10]\]. Severe side effects, such as xerostomia and difficulty in swallowing can lead to malnutrition, which is associated with poor prognosis \[[@CR10], [@CR24]\]. Joel Castelli et al. noted that anatomical changes during IMRT were the main cause of overdose to the PGs \[[@CR10]\]. The average volume of the PGs decreased by 28% during radiotherapy, and the weekly re-planning could account for the changes in the volume of the PGs in real time. The Dmean for the PGs decreased by an average of 5 Gy, and the risk of xerostomia decreased by 11% \[[@CR10]\]. The Dmean to the PGs is associated with the volume of PGs during radiotherapy \[[@CR25]--[@CR30]\], and there was a difference between the delivered dose and the planned dose to the PGs during radiotherapy. Brouwer also demonstrated that the Dmean to the PGs in patients with HNC significantly increased during radiotherapy, and ART reduced the Dmean to the PGs, thus alleviating the symptoms of xerostomia \[[@CR4]\]. Deng et al. noted that patients with NPC who received IMRT experienced significant anatomical changes during the course of treatment, and ART was necessary to maintain optimal doses to targets and OAR. Patients with NPC who were subjected to re-planning at cycles 5 and 15 were compared with patients who only received IMRT. The planning target volume in the ART group were significantly improved. Compared with those in the IMRT group, the Dmean to the PGs in the ART+IMRT group decreased by 1.27 ± 1.05 Gy, the V50 to the PGs decreased by 4.12 ± 3.58%, and the V55 for the skin decreased by 0.91 ± 1.83% \[[@CR31]\].

Myelosuppression is a common side effect of radiotherapy. When myelosuppression occurs, haematopoietic stem cells cannot produce enough normal blood cells, which leads to complications such as anaemia, infection and bleeding, and these complications seriously affect the survival of patients. Moreover, as inflammation plays an important role in tumour development \[[@CR32]\], many studies have suggested that inflammation-related factors (such as the NLR, lymphocyte count, and neutrophil count) in the blood can predict the prognosis of patients, \[[@CR32]--[@CR39]\] and these parameters can be evaluated by conventional examinations. Several studies have shown that a decrease in lymphocyte count in the peripheral blood of patients with NPC is associated with poor OS and PFS \[[@CR33], [@CR34], [@CR36], [@CR37]\], and that the neutrophil count is related to OS, DSS, and DMFS \[[@CR33], [@CR38]\]. The NLR was also thought to be associated with prognosis in many types of cancers \[[@CR39]--[@CR41]\], and a higher NLR is related to poor prognosis \[[@CR42]--[@CR47]\]. A meta-analysis by Yukinori Takenaka demonstrated that elevated NLR was associated with poor OS, DSS, PFS, and DMFS \[[@CR48]\]. In our study, 12 (24%) patients treated with ART+IMRT had a lower NLR after treatment than that before; additionally, 41 (81%) patients experienced a decrease in the CLC, 36 (72%) patients experienced a decrease in the CNC, and 31 (62%) patients experienced a decrease in the CPC after treatment. For the IMRT group, these number were 3 (6%), 48 (96%), 24 (48%), and 38 (76%), respectively. Patients in the ART and IMRT groups demonstrated significant differences in the ΔNLR (*P* \< 0.001), ΔCLC (P \< 0.001), ΔCNC (*P* = 0.045), and ΔCPC (*P* = 0.03). This finding supports the changes in haematological parameters during radiotherapy in patients. ART can ameliorate the decrease in haematological parameters during radiotherapy and mitigate myelosuppression after radiotherapy.

Furthermore, correlation analysis and regression analysis showed that ART was an independent factor influencing haematological parameters (ΔNLR, ΔCLC, and ΔCPC). A study of cervical cancer patients by Emily et al. suggested that pre-treatment total lymphocyte count (TLC) ≥1000 cells/mm3 and post-treatment TLC \> 500 cells/mm3 indicated a 77% (hazard ratio (HR): 0.23; 95% confidence interval (CI): 0.05--1.03; *P* = 0.053) and 58% decrease in the risk of death (HR: 0.42; 95% CI: 0.12--1.46; *P* = 0.17), respectively \[[@CR8]\]. Unfortunately, no such studies have recently been conducted for HNC.

A retrospective study in 2016 suggested that ART can improve the prognosis of patients with NPC. The study followed 132 NPC patients (66 receiving ART and 66 receiving IMRT), and the 5-year LRFS rate was higher in the IMRT re-planning group than in the IMRT only group (96.7 vs. 88.1%, *P* = 0.022). Distant metastasis remains the main pattern of treatment failure. A total of 21.2% patients in the IMRT re-planning group and 28.8% patients in the IMRT only group had distant metastasis \[[@CR21]\]. Two previous studies have also suggested that ART improves clinical outcomes in patients with HNC, including improvements in local control and reductions in late side effects \[[@CR3], [@CR21]\]. However, based on our follow-up data, the differences in OS, PFS, DMFS, and LRFS were not statistically significant, although 3 (6%) patients in the ART+IMRT group 9 (18%) patients in the IMRT group experienced local recurrence. During the course of radiotherapy, most patients experienced anatomical changes, such as tumour shrinkage and weight loss, resulting in an insufficient dose to the target area \[[@CR2]\], which greatly improved the LRFS rate of patients. ART can alleviate these anatomical changes to maintain a satisfactory dose to the target volumes \[[@CR21]\].

Although studies have shown that patients with the same TNM stage may have different clinical outcomes \[[@CR49]--[@CR51]\], TNM stages remain the standard for predicting prognosis and stratification of patients in studies. In our study, patients were separated according to their TNM stage. The results showed that the change in haematological parameters of patients with stage T1--2 disease was significantly better than that of patients with stage T3--4 disease. Notably, the number of patients in this study was limited.

Conclusion {#Sec17}
==========

Our study compared changes in side effects, haematologic parameters and weight during radiotherapy between patients receiving ART+IMRT and IMRT alone. We found that ART had an effect on the side effects and the change in haematologic parameters during radiotherapy, and patients with T1--2 disease experienced a greater benefit. According to the follow-up, the differences in OS, PFS, LRFS and DMFS were not statistically significant, but the number of local recurrences in the IMRT group was higher than that in the ART+IMRT group. Nevertheless, these results are preliminary and need to be validated.

Additional file
===============

 {#Sec18}

Additional file 1:Patient characteristics and radiotherapy-related variables between the two groups. (XLSX 23 kb)
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